PTCT, US69366J2006

Cantor raises target for PTC Therapeutics stock to USD 137.00

Published on 10/07/2026 at 03:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 101.50 percent to USD 360.52 million in the second quarter. PTC Therapeutics stock had an EUR 56.57 prior close on October 5, 2026.

PTCT, US69366J2006, Illustration mit AI erstellt.

PTC Therapeutics (ISIN US69366J2006) received a higher Cantor Fitzgerald price target of USD 137.00 from USD 130.00 on September 22, 2026, with the firm maintaining its Overweight rating, according to Investing.com. The move followed PTC's expansion into Fabry disease through the ST-920 program.

ST-920 expands the rare disease pipeline

PTC completed its acquisition of ST-920 from Sangamo Therapeutics on September 21, 2026, according to The Globe and Mail. The transaction added a BLA-stage, one-time administered gene therapy candidate, while PTC expects to complete a rolling biologics license application submission to the FDA in the fourth quarter of 2026.

The acquisition carries a USD 111.00 million upfront payment and up to USD 100.00 million in contingent regulatory payments, figures that frame the pipeline expansion against the company's operating scale. The regulatory timetable is the key execution point because the asset remains dependent on filing and review milestones.

Second-quarter revenue doubled year over year

PTC reported USD 360.52 million of revenue in the second quarter of 2026, up 101.50 percent from the same quarter a year earlier, according to MarketBeat. Diluted earnings per share were USD 0.92 versus a USD 0.24 consensus estimate, a USD 0.68 difference that gives the latest results a clear comparison point.

The finance statements show USD 129.11 million of operating cash flow in the second quarter of 2026, compared with negative USD 59.04 million in the first quarter. Cash and cash equivalents stood at USD 1.05 billion on June 30, 2026, supporting continued investment in clinical and commercial programs.

Results date sets the next checkpoint

Investing.com lists October 22, 2026, as PTC's next earnings date and reports an average analyst target of USD 101.79. Against the Cantor target of USD 137.00, the range of views shows that valuation depends heavily on the pace of Sephience commercialization and the regulatory progress of newer assets.

Lang & Schwarz lists a prior close of EUR 56.57 for October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of PTC Therapeutics stock.